Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 1

62MO - A randomised, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in locally advanced NSCLC


11 Dec 2020


Mini Oral session 1


Jie Lei


Annals of Oncology (2020) 31 (suppl_7): S1441-S1451. 10.1016/annonc/annonc392


J. Lei1, X. Yan2, J. Zhao2, F. Tian2, Q. Lu2

Author affiliations

  • 1 Tangdu hospital, The Fourth Military Medical University, 710038 - Xi’an City/CN
  • 2 Tangdu hospital, The Fourth Military Medical University, Xi’an City/CN


Login to access the resources on OncologyPRO.

Abstract 62MO


Camrelizumab (Cam), an anti-PD-1 antibody, could significantly increase the PFS and ORR in advanced non-squamous NSCLC vs chemotherapy (CT). However, the effect and safety of Cam plus CT in the neoadjuvant setting is unknown.


This interim analysis included 27 patients (pts) with locally advanced NCSLC. Treatment-naive pts with stage IIIA or IIIB-N2 resectable NSCLC, ECOG PS 0-1, were randomized (1:1) to receive intravenous Cam (200mg) on D1, albumin-bound paclitaxel (ab-Pac; 130 mg/m2) on D1 and 8, and cisplatin (Cis; 75 mg/m2) on D1 (Cam+CT group), or ab-Pac plus Cis (CT group) of a 21-day cycle for 3 cycles. Treatment was followed by surgery. The primary endpoint was pathologic complete response (pCR). Secondary endpoints included major pathologic response (MPR), ORR, DFS by RECIST 1.1, and safety. The immune-related gene profiles of pre- or post-treatment biopsies and serum were detected to construct the individualized immune signature for outcome prediction through a multicenter analysis. 94 patients were planned to be enrolled.


At data cutoff (Sept 15, 2020), 27 pts were enrolled (14 in the Cam+CT group and 13 in the CT group). All pts received at least 1 cycle treatment. 14 pts completed neoadjuvant therapy and efficacy evaluation, among which 13 had surgery (7 in the Cam+CT group and 6 in the CT group) and 1 was pending for surgery. In the Cam+CT group, pCR was observed in 4/7 (57.1%) pts and MPR in 2 (28.6%); ORR was 86.7% (6/7; CR: 1, PR: 5). In the CT arm, 1/6 (16.7%) pts achieved pCR and 1 (16.7%) had MPR; ORR was 57.1% (4/7; CR: 1, PR: 3). DFS data was immature and gene profiles will be analyzed later. Adverse events (AEs) of the two arms were similar, except reactive cutaneous capillary endothelial proliferation (9/14 [64.3%]; all grade 1) in the Cam+CT arm. No AEs beyond expectation or of grade 4-5 were reported.


These interim results suggested camrelizumab plus CT may have a better effect as neoadjuvant therapy in locally advanced NSCLC. This trial is ongoing and final analysis will be conducted after study completion.

Clinical trial identification


Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.